<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775212</url>
  </required_header>
  <id_info>
    <org_study_id>AP2101-50101</org_study_id>
    <nct_id>NCT04775212</nct_id>
  </id_info>
  <brief_title>Desflurane and Sevoflurane in Pediatrics With Elevated Liver Enzymes</brief_title>
  <official_title>Effects of Desflurane and Sevoflurane Anesthesia on Postoperative Liver Functions in Pediatric Cancer Patients With Elevated Liver Enzymes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is designed to compare effects of inhaled anaesthetic desflurane and sevoflurane on liver&#xD;
      functions in pediatric cancer patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly allocated into two groups using a sealed envelope technique:&#xD;
      desflurane group (Des group, n = 30) and sevoflurane group (sevo group, n = 30).&#xD;
&#xD;
      Anesthesia monitoring included electrocardiogram, continuous arterial and pulse oximetry,&#xD;
      capnography, urine output, nerve stimulator, and esophageal core temperature.&#xD;
&#xD;
      Anesthesia will be induced with Propofol 2 mg/kg ,FentanyL 2 μg/kg and atracurium (0.5 mg/kg)&#xD;
      was administered to achieve muscle relaxation before endotracheal intubation. End-tidal&#xD;
      desflurane or sevoflurane concentrations during the induction were limited to 2 minimal&#xD;
      alveolar concentration (MAC). Concentrations of inhalational anesthetics were measured using&#xD;
      an anesthetic gas analyser (Datex-Ohmeda, Helsinki, Finland). For the maintenance of&#xD;
      anesthesia, the inspired desflurane or sevoflurane concentration was carefully titrated to&#xD;
      maintain the end-tidal concentration of 1 MAC. A constant fresh gas flow of 3 l/min&#xD;
      (medical-grade air in oxygen to make inspiratory oxygen fraction 0.5) was used during the&#xD;
      maintenance of anesthesia. Ventilation was controlled with a tidal volume of 7-10 ml/kg and&#xD;
      ventilatory rate was adjusted to maintain an end tidal carbon dioxide ( CO2 )of 35-40 mmHg.&#xD;
      to maintain intraoperative blood pressure (BP) and heart rate (HR) within 20% of preoperative&#xD;
      values. additional Atracurium will be administered as appropriate. Nerve stimulator was used&#xD;
      to monitor neuromuscular blockade on the right adductor pollicis. Hypotension (a drop in&#xD;
      systolic BP to the extent of 30% or more or the systolic BP being less than the preoperative&#xD;
      values) was treated with volume replacement and, when necessary, with intravenous ephedrine&#xD;
      in incremental doses .Bradycardia (HR &lt; 50 beats per min) was treated with atropine if&#xD;
      needed.&#xD;
&#xD;
      Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB),&#xD;
      prothrombin time (PT) expressed in international normalized ratio (INR), albumin, platelet&#xD;
      count (PLT), and hemoglobin (Hb) were analysed at preoperative period, immediately after&#xD;
      operation, and on the 1st, 2nd, 3rd, 5th and 7th, postoperative days (PODs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver function test</measure>
    <time_frame>6 months</time_frame>
    <description>measuring Aspartate aminotransferase (AST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALT</measure>
    <time_frame>6 months</time_frame>
    <description>measuring alanine aminotransferase (ALT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total bilirubin</measure>
    <time_frame>6 months</time_frame>
    <description>measuring total bilirubin (TB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>prothrombin time</measure>
    <time_frame>6 months</time_frame>
    <description>measuring prothrombin time (PT) expressed in international normalized ratio (INR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>6 months</time_frame>
    <description>measuring level of albumin.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Functions Tests</condition>
  <arm_group>
    <arm_group_label>desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients to be anesthetized with desflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients to be anesthetized with sevoflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desﬂurane</intervention_name>
    <description>compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.</description>
    <arm_group_label>desflurane</arm_group_label>
    <other_name>Suprane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane</description>
    <arm_group_label>sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;1 year and &lt; 12 years old.&#xD;
&#xD;
          -  Estimated time of surgeries within 1-3 hours.&#xD;
&#xD;
          -  Elevated liver enzymes less than triple folds.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal.&#xD;
&#xD;
          -  Hepatitis positive patients.&#xD;
&#xD;
          -  Raising liver enzymes.&#xD;
&#xD;
          -  Hepatic surgeries.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>2-18 years old</gender_description>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzan Adlan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National cancer institute</name>
      <address>
        <city>Cairo</city>
        <zip>11769</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Norma Osama Abdalla Zayed</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>Desflurane,Sevoflurane,liver enzymes,cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

